Literature DB >> 18664989

Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy.

Bradley S Buckler1, Ralph N Sams, Vita L Goei, Karthik R Krishnan, Marci J Bemis, Deidrea P Parker, Dennis L Murray.   

Abstract

The current standard of care for a fungal central venous catheter infection in a pediatric patient usually requires removal without any other feasible options. Although removal may reduce the rate of Candida-associated complications, literature reviews question whether the outcomes of removal substantiate this being the standard of care. We report 6 cases of central venous catheter fungal infections treated with liposomal amphotericin-B lock therapy. These cases consisted of 4 patients, 2 of whom received recurrent therapy. In 4 of these cases, there was successful eradication of the infectious fungal agent, allowing continued use of the catheter. A controlled study of antifungal lock therapy should be considered as a potential alternative to removal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664989     DOI: 10.1097/INF.0b013e318170b68b

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  17 in total

1.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

2.  Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole.

Authors:  Anna Bink; Davy Vandenbosch; Tom Coenye; Hans Nelis; Bruno P A Cammue; Karin Thevissen
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

3.  In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms.

Authors:  Kwan Soo Ko; Ji-Young Lee; Jae-Hoon Song; Kyong Ran Peck
Journal:  J Korean Med Sci       Date:  2010-11-24       Impact factor: 2.153

Review 4.  Antifungal lock therapy.

Authors:  Carla J Walraven; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

5.  Combination of Miconazole and Domiphen Bromide Is Fungicidal against Biofilms of Resistant Candida spp.

Authors:  Jana Tits; Freya Cools; Kaat De Cremer; Katrijn De Brucker; Judith Berman; Kristof Verbruggen; Bert Gevaert; Paul Cos; Bruno P A Cammue; Karin Thevissen
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 6.  Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.

Authors:  Neil R H Stone; Tihana Bicanic; Rahuman Salim; William Hope
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

Review 7.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

Review 8.  Reducing the risk of infection associated with vascular access devices through nanotechnology: a perspective.

Authors:  Li Zhang; Samantha Keogh; Claire M Rickard
Journal:  Int J Nanomedicine       Date:  2013-11-21

Review 9.  The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia.

Authors:  Emilio Bouza; Jesús Guinea; María Guembe
Journal:  Antibiotics (Basel)       Date:  2014-12-25

Review 10.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.